PDGFR blockade is a rational and effective therapy for NPM-ALK–driven lymphomas
Daniela Laimer(Medical University of Vienna), Helmut Dolznig(Medical University of Vienna), Karoline Kollmann(University of Vienna), Paul Vesely(Scripps Research Institute), Michaela Schlederer(Ludwig Boltzmann Institute for Cancer Research), Olaf Merkel(Scripps Research Institute), Ana Iris Schiefer(Medical University of Vienna), Melanie R. Hassler(Medical University of Vienna), Susi Heider(Medical University of Vienna), Lena Amenitsch(Medical University of Vienna), Christiane Thallinger(Medical University of Vienna), Philipp B. Staber(Harvard University), Ingrid Simonitsch‐Klupp(Medical University of Vienna), Matthias Artaker(Max Perutz Labs), Sabine Lagger(Scripps Research Institute), Suzanne D. Turner(University of Cambridge), Stefano Pileri(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Pier Paolo Piccaluga(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Peter Valent(Ludwig Boltzmann Institute for Cardiovascular Research), Katia Messana(University of Turin), Indira Landra(University of Turin), Thomas Weichhart(Medical University of Vienna), Sylvia Knapp(Austrian Academy of Sciences), Medhat Shehata(Comprehensive Cancer Center Vienna), Maria Chiara Todaro(University of Turin), Veronika Sexl(University of Vienna), Gerald Höfler(Medical University of Graz), Roberto Piva(University of Turin), Enzo Médico(Candiolo Cancer Institute), Bruce Ruggeri, Mangeng Cheng, Robert Eferl(Comprehensive Cancer Center Vienna), Gerda Egger(Medical University of Vienna), Josef Penninger(Institute of Molecular Biotechnology), Ulrich Jaeger(Comprehensive Cancer Center Vienna), Richard Moriggl(Ludwig Boltzmann Institute for Cancer Research), Giorgio Inghirami(University of Turin), Lukas Kenner(Ludwig Boltzmann Institute for Cancer Research)
Cited by 125Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis